Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Dilip Shanghvi to continue as the Executive Chairman of the Board
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
EBITDA for the period rose by 23.2% to Rs. 3,797 million
Subscribe To Our Newsletter & Stay Updated
